Table 1 Patient and tumor characteristics at the time of first 21-gene testing in the study cohort and the general 21-gene-tested BC cohort by nodal status.
N0 | N1mi/N1 | |||||
|---|---|---|---|---|---|---|
Characteristics | Study cohort n = 46 | General 21-gene-tested BC cohort n = 1340 | p* | Study cohort n = 14 | General 21-gene-tested BC cohort n = 704 | p* |
Median (IQR) age at testing, years | 55.5 (43.3–61.0) | 60.0 (52.8–66.0) | 0.002 | 55.5 (47.8–65.3) | 62.0 (53.0–67.0) | 0.15 |
Median (IQR) tumor size, cm | 1.5 (1.0–2.15) | 1.5 (1.1–2.0) | 0.70 | 2.0 (1.3–2.4) | 1.7 (1.3–2.3) | 0.39 |
Tumor size category, n (%) | ||||||
≤1 cm | 14 (30.4%) | 290 (21.6%) | 0.33 | 1 (7.1%) | 114 (16.2%) | 0.62 |
>1–2 cm | 20 (43.5%) | 744 (55.5%) | 7 (50.0%) | 377 (53.6%) | ||
>2 cm | 12 (26.1%) | 296 (22.1%) | 6 (42.9%) | 205 (29.1%) | ||
Not available | 0 (0) | 10 (0.7%) | 0 (0) | 8 (1.1%) | ||
Tumor grade category, n (%) | ||||||
Grade 1 | 7 (15.2%) | 192 (14.3%) | 0.44 | 2 (14.3%) | 101 (14.3%) | 0.51 |
Grade 2 | 28 (60.9%) | 674 (50.3%) | 4 (28.6%) | 380 (54.0%) | ||
Grade 3 | 5 (10.9%) | 217 (16.2%) | 5 (35.7%) | 111 (15.8%) | ||
Not available | 6 (13.0%) | 257 (19.2%) | 3 (21.4%) | 112 (15.9%) | ||
Histology, n (%) | ||||||
IDC | 39 (84.8%) | 1082 (80.7%) | 0.73 | 11 (78.6%) | 591 (83.9%) | 0.67 |
ILC | 3 (6.5%) | 159 (11.9%) | 2 (14.3%) | 85 (12.1%) | ||
Mucinous/ colloid/papillary | 2 (4.3%) | 54 (4.0%) | 0 (0) | 11 (1.6%) | ||
Not available | 2 (4.3%) | 45 (3.4%) | 1 (7.1%) | 17 (2.4%) | ||
Nodal status, n (%) | ||||||
N0 | 46 (100%) | 1340 (100%) | NA | 0 (0) | 0 (0) | |
N1mi | 0 (0) | 0 (0) | 6 (42.9%) | 294 (41.8%) | 0.71 | |
N1 | 0 (0) | 0 (0) | 8 (57.1%) | 410 (58.2%) | ||
